

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-24. (canceled)

25.(New): An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23. SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, or variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23. SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, in which one or more amino acids are replaced, deleted, inserted and/or added.

26. (New): An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24. SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, or variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10 or SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24. SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.

27. (New): An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 19, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1 SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13 or SEQ ID NO: 17, in which one or more amino acids are replaced, deleted, inserted and/or added.

28. (New): An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14 or SEQ ID NO: 18, in which one or more amino acids are replaced, deleted, inserted and/or added.

29. (New): The polypeptide of claim 25 contained in a suitable pharmaceutical composition for delivery to a subject.

30. (New): The polypeptide of claim 29, wherein in the subject is human.

31. (New): The polypeptide of claim 26 contained in a suitable pharmaceutical composition for delivery to a subject.

32. (New): The polypeptide of claim 29, wherein in the subject is human.

33. (New): The polypeptide of claim 25, comprising one or more antigenic polypeptide sequences.

34. (New): The polypeptide of claim 33, wherein the one or more antigenic polypeptide sequences specifically binds to one or more isolated antibodies.

35. (New): The polypeptide of claim 26, comprising one or more antigenic polypeptide sequences.

36. (New): The polypeptide of claim 35, wherein the one or more antigenic polypeptide sequences specifically binds to one or more isolated antibodies.

37. (New): The polypeptide of claim 25, wherein the polypeptide binds to a binding partner located on a cell membrane with a  $K_d$  of approximately  $10^{-8}M$  or greater.

38. (New): The polypeptide of claim 37, wherein when the polypeptide binds to the binding partner located on the cell membrane, the binding produces a molecular signal that is transmitted to the interior of the cell.

39. (New): The polypeptide of claim 26, wherein the polypeptide binds to a binding partner located on a cell membrane with a  $K_d$  of approximately  $10^{-8}M$  or greater.

40. (New): The polypeptide of claim 39, wherein when the polypeptide binds to the binding partner located on the cell membrane, the binding interaction produces a molecular signal that is transmitted to the interior of the cell.

41.(New): The polypeptide of claim 27, wherein the nucleic acid sequence corresponding to the peptide is contained in a suitable nucleic acid vector for delivery into a cell, and wherein the vector contained in the cell permits expression of the polypeptide within the cell.

42. (New): The polypeptide of claim 41, wherein the expressed polypeptide is subsequently secreted from the cell.

43. (New): The polypeptide of claim 28, wherein the nucleic acid sequence corresponding to the peptide is contained in a suitable nucleic acid vector for delivery into a cell, and wherein the vector contained in the cell permits expression of the polypeptide within the cell.

44. (New): The polypeptide of claim 43, wherein the expressed polypeptide is subsequently bound to the cell membrane.